Management of treatment resistant obsessive-compulsive disorder: Algorithms for pharmacotherapy

Panminerva Medica

Volumn 44, Issue 2, 2002, Pages 83-91

  Albert, U ^a   Bergesio, C ^a   Pessina, E ^a   Maina, G ^a   Bogetto, F ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Obsessive compulsive disorder, drug therapy; Serotonin uptake inhibitors, administration and dosage; Serotonin uptake inhibitors, therapeutic use

Indexed keywords

CITALOPRAM; CLOMIPRAMINE; DOPAMINE RECEPTOR BLOCKING AGENT; SEROTONIN UPTAKE INHIBITOR;

ALGORITHM; COGNITIVE THERAPY; DRUG COMBINATION; DRUG RESISTANCE; HUMAN; MULTIMODALITY CANCER THERAPY; OBSESSIVE COMPULSIVE DISORDER; REVIEW;

ALGORITHMS; CITALOPRAM; CLOMIPRAMINE; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; DOPAMINE ANTAGONISTS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; HUMANS; OBSESSIVE-COMPULSIVE DISORDER; SEROTONIN UPTAKE INHIBITORS;

EID: 0036617139     PISSN: 00310808     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (83)

1. Clomipramine Collaborative Study Group. Efficacy of clomipramine in OCD: results of a multicenter double blind trial. Arch Gen Psychiatry 1991;48:730-8.
2. Montgomery S, Bullock T, Fineberg N, Montgomery D. Selective serotonin reuptake inhibitors in OCD. Clin Neuropsychopharmacol 1992;15:255-6.
3. Tollefson G, Rampey A, Potvin J, Jenike MA, Rush AJ, Kominguez RA et al. A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 1994;51:559-67.
4. Goodman WK, Kozak MJ, Liebowitz M, White KL. Treatment of obsessive-compulsive disorder with fluvoxamine: a multicentre, double-blind, placebo-controlled trial. Int Clin Psychopharmacol 1996;11:21-9.
5. Greist HJ, Chouinard G, DuBoff E, Halaris A, Kim SW, Koran L et al. Double-blind parallel comparison of 3 dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. Arch Gen Psychiatry 1995;52:289-95.
6. Greist HJ, Jenike MA, Robinson D. Efficacy of fluvoxamine in obsessive-compulsive disorder: results of a multicentre, double-blind, placebo-controlled trial. Eur J Clin Res 1995;7:195-204.
7. Zohar J, Judge R. Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. Br J Psychiatry 1996;169:468-74.
8. Mundo E, Maina G, Uslenghi C. Multicentre, double-blind, comparison of fluvoxamine and clomipramine in the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol 2000;15(2):69-76.
9. Montgomery SA, Kasper S, Stein DJ, Bang Hedergaard K, Lemming OM. Citalopram 20 mg, 40 mg, and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder. Int Clin Psychopharmacol 2001;16(2):75-86.
10. Rasmussen SA, Eisen LJ, Paro MT. Current issues in the pharmacologic management of obsessive-compulsive disorder. J Clin Psychiatry 1993;54(Suppl):4-9.
11. Rauch SL, Jenike MA. Management of treatment-resistant obsessive-compulsive disorder: concepts and strategies. In: Hollander E, Zohar J, Marazziti D, Olivier B, editors. Current insights in obsessive-compulsive disorder. Chichester: John Wiley & Sons Ltd., 1994.
12. March J, Frances A, Carpenter D, Kahn D, editors. The Expert Consensus Guideline Series. Treatment of obsessive-compulsive disorder. J Clin Psychiatry 1997;58(Suppl 4):1-70.
13. Greist JH, Jefferson JW. Pharmacotherapy for obsessive-compulsive disorder. Br J Psychiatry 1998;173(Suppl 35):64-70.
14. O'Reardon JP, Amsterdam JD. Overview of treatment-resistant depression and its management. In: Amsterdam JD, Hornig M, Nieremberg AA, editors. Treatment-resistant mood disorders. Cambridge, UK: Cambridge University Press, 2001:30-45.
15. Warneke LB. Intravenous chlorimipramine therapy in obsessive-compulsive disorder. Can J Psychiatry 1989;34:853-9.
16. Fallon BA, Liebowitz MR, Campeas R, Schneier FR, Marshall R, Davies S et al. Intravenous clomipramine for obsessive-compulsive disorder refractory to oral clomipramine. Arch Gen Psychiatry 1998;55:918-24.
17. Koran LM, Faravelli C, Pallanti S. Intravenous clomipramine for obsessive-compulsive disorder. J Clin Psychopharmacol 1994;14(3):216-8.
18. Koran LM, Sallee FR, Pallanti S. Rapid benefit of intravenous pulse loading of clomipramine in obsessive-compulsive disorder. Am J Psychiatry 1997;154:396-401.
19. Koran LM, Pallanti S, Paiva RS, Quercioli L. Pulse loading versus gradual dosing of intravenous clomipramine in obsessive-compulsive disorder. Eur Neuropsychopharmacol 1998;8(2):121-6.
20. Simpson HB, Gorfinkle KS, Liebowitz MR. Cognitive-behavioral therapy as an adjunct to serotonin reuptake inhibitors in obsessive-compulsive disorder: an open trial. J Clin Psychiatry 1999;60(9):584-90.
21. Simeon JG, Thatte S, Wiggings D. Treatment of adolescent obsessive-compulsive disorder with a clomipramine-fluoxetine combination. Psychopharmacol Bull 1990;26(3):285-90.
22. Ravizza L, Barzega G, Bellino S, Bogetto F, Maina G. Therapeutic effect and safety of adjunctive risperidone in refractory obsessive-compulsive disorder (OCD). Psychopharmacol Bull 1996;32(4):677-82.
23. Pallanti S, Quercioli L, Paiva RS, Koran LM. Citalopram for treatment-resistant obsessive-compulsive disorder. Eur Psychiatry 1999;14(2):101-6.
24. McDougle CJ, Price LH, Goodman WK. A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: lack of efficacy. J Clin Psychopharmacol 1991;11:175-84.
25. Pigott TA, L'Heureux F, Hill JL, Bihari K, Bernstein SE, Murphy DL. A double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated patients with obsessive-compulsive disorder. J Clin Psychopharmacol 1992;12:11-8.
26. Grady TA, Pigott TA, L'Eureux F, Hill JL, Bernstein SE, Murphy DL. Double-blind study of adjuvant buspirone for fluoxetine-treated patients with obsessive-compulsive disorder. Am J Psychiatry 1993;150:818-21.
27. McDougle, Goodman WK, Leckman JF, Holzer JC, Barr LC, McCance-Katz E et al. Limited therapeutic effect of addition of buspirone in fluvoxamine- refractory obsessive-compulsive disorder. Am J Psychiatry 1993;150:647-9.
28. Judd FK, Chua P, Lynch C, Norman T. Fenfluramine augmentation of clomipramine treatment of obsessive-compulsive disorder. Aust N Z J Psychiatry 1991;25:412-4.
29. Hollander E, DeCaria CM, Schneier FR, Schneier HA, Liebowitz MR, Klein DF. Fenfluramine augmentation of serotonin reuptake blockade antiobsessional treatment. J Clin Psychiatry 1990;51:119-23.
30. Yayura-Tobias JA, Bhagavan HN. L-tryptophan in ossessive-compulsive disorder. Am J Psychiatry 1977;134(11):1298-9.
31. Rasmussen SA. Lithium and tryptophan augmentation in clomipramine- resistant obsessive-compulsive disorder. Am J Psychiatry 1984;141:1283-5.
32. McDougle CJ, Goodman WK, Price LH, Delgado PL, Krystal JH, Charney DS. Neuroleptic addition in fluvoxamine-refractory obsessive-compulsive disorder. Am J Psychiatry 1990;147:652-4.
33. Jenike MA. Management of patients with treatment resistant obsessive-compulsive disorder. In: Pato MT, Zohar J, editors. Current treatments of obsessive-compulsive disorders. Washington, DC: American Psychiatric Press., 1991:135-55.
34. McDougle, Goodman WK, Leckman JF, Lee NC, Heninger GR, Price LH. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind placebo-controlled study in patients with and without tics. Arch Gen Psychiatry 1994;51:302-8.
35. Jacobsen FM. Risperidone in the treatment of affective illness and obsessive-compulsive disorder. J Clin Psychiatry 1995;56:423-9.
36. McDougle CJ, Fleischman RL, Epperson CN, Wasylink S, Leckman JF, Price LH. Risperidone addition in fluvoxamine-refractory obsessive-compulsive disorder: three cases. J Clin Psychiatry 1995;56:526-8.
37. Saxena S, Wang D, Bystritsky A, Baxter LR Jr. Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder. J Clin Psychiatry 1996;57:303-6.
38. Stein DJ, Bouwer C, Hawkridge S, Emsley RA. Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders. J Clin Psychiatry 1997;58:119-22.
39. Pfanner C, Marazziti D, Dell'Osso L, Presta S, Gemignani A, Milanfranchi A et al. Risperidone augmentation in refractory obsessive-compulsive disorder: an open-label study. Int Clin Psychopharmacol 2000;15:297-301.
40. Weiss EL, Potenza MN, McDougle CJ, Epperson CN. Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series. J Clin Psychiatry 1999;60:524-7.
41. Bogetto F, Bellino S, Vaschetto P, Ziero S. Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial. Psychiatr Res 2000;96:91-8.
42. Koran LM, Ringold AL, Elliott MA. Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry 2000;61:514-7.
43. Francobandiera G. Olanzapine augmentation of serotonin uptake inhibitors in obsessive-compulsive disorder: an open study. Can J Psychiatry 2001;46(4):356-8.
44. McDougle CJ, Epperson CN, Pelton GH, Wasylink S, Price LH. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry 2000;57:794-801.
45. th IOCDC. Sardinia, Italy, March 29-April 1, 2001.
46. Hollander E, Fay M, Liebowitz MR. Clonidine and clomipramine in obsessive-compulsive disorder. Am J Psychiatry 1988;145:388-9.
47. th Annual Meeting of the American Psychiatric Association. Washington, DC: American Psychiatric Association, 1992:82 (Abstract NR 144).
48. Leonard HL, Topol D, Bukstein O, Hindmarsh D, Allen AJ, Swedo SE. Clonazepam as an augmenting agent in the treatment of childhood-onset obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 1994;33:792-4.
49. Cora-Locatelli G, Greenberg BD, Martin J, Murphy DL. Gabapentin augmentation for fluoxetine-treated patients with obsessive-compulsive disorder. J Clin Psychiatry 1998;59:480-1.
50. nd Annual Meeting of the American Psychiatric Association. Washington, DC: American Psychiatric Association, 1999:15-20.
51. Seedat S, Stein DJ. Inositol augmentation of serotonin reuptake inhibitors in treatment-refractory obsessive-compulsive disorder: an open trial. Int Clin Psychopharmacol 1999;14(6):353-6.
52. Kumar TC, Khanna S. Lamotrigine augmentation of serotonin reuptake inhibitors in obsessive-compulsive disorder. Aust N Z J Psychiatry 2000;34(3):527-8.
53. Iwata Y, Kotani Y, Hoshino R, Takei N, Iyo M, Mori N. Carbamazepine augmentation of clomipramine in the treatment of refractory obsessive-compulsive disorder. J Clin Psychiatry 2000;61(7):528-9.
54. Fux M, Benjamin J, Belmaker RH. Inositol versus placebo augmentation of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: a double-blind, cross-over study. Int J Psychopharmacol 1999;2(3):193-5.
55. Blier P, Bergeron R. Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. J Clin Psychopharmacol 1996;15(3):217-22.
56. Bakish D, Hooper CL, Thornton MD, Wiens A, Miller CA, Thibaudeau CA. Rapid onset: an open study of the treatment of major depressive disorder with nefazodone and pindolol combination therapy. Int Clin Psychopharmacol 1997;12(2):91-7.
57. Blier P, Bergeron R. The use of pindolol to potentiate antidepressant medication. J Clin Psychiatry 1998;59:16-23.
58. Bordet R, Thomas P, Dupuis B. Effect of pindolol on onset of action of paroxetine in the treatment of major depression: intermediate analysis of a double-blind, placebo-controlled trial. Reseau de Recherche et d'Experimentation Psychopharmacologique. Am J Psychiatry 1998;155:1346-51.
59. Moreno FA, Gelenberg AJ, Bachar K, Delgado PD. Pindolol-augmentation of treatment-resistant depressed patients. J Clin Psychiatry 1997;58:437-9.
60. Perez V, Soler J, Puigdemont D, Alvarez E, Artigas F. A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. Arch Gen Psychiatry 1999;56:375-9.
61. Mundo E, Guglielmo E, Bellodi L. Effect of adjuvant pindolol on the antiobsessional response to fluvoxamine: a double-blind placebo-controlled study. Int Clin Psychopharmacol 1998;13:219-24.
62. Dannon PN, Sasson Y, Hirschmann S, Iancu I, Grunhaus LJ, Zohar J. Pindolol augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind placebo controlled trial. Eur Neuropsychopharmacol 2000;10:165-9.
63. Jenike MA. Drug treatment of obsessive-compulsive disorder. In: Jenike MA, Baer L, Minichiello WE, editors. Obsessive-compulsive disorders: theory and management. Chicago: Year Book Medical Publishing, 1990:249-82.
64. Greist HJ. An integrated approach to treatment of obsessive-compulsive disorder. J Clin Psychiatry 1992;53(Suppl 4):38-41.
65. Goodman WK, McDougle CJ, Barr LC, Aronson SC, Price LH. Biological approaches to treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry 1993;54(Suppl 6):16-26.
66. Zohar J, Ayuso-Gutierrez JL, D'Haenen H. Treatment of obsessive-compulsive disorder: algorithms for pharmacotherapy. Int J Psych Clin Pract 1997;1:517-23.
67. Brown WA, Harrison W. Are patients who are intolerant to one serotonin selective reuptake inhibitor intolerant to another? J Clin Psychiatry 1995;56(1):30-4.
68. Thase ME, Biomgren SL, Birkett HA, Apter JT, Tepner RG. Fluoxetina treatment of patients with major depressive disorder who failed initial treatment with sertraline. J Clin Psychiatry 1997;58(1):16-21.
69. Joffe TR, Levitt AJ, Sokolov ST, Young LT. Response to an open trial of a second SSRI in major depression. J Clin Psychiatry 1996;57:114-5.
70. Zarate CA Jr, Kando JC, Tohen M, Weiss MK, Cole JO. Does intolerance or lack of response with fluoxetine predict the same will happen with sertraline? J Clin Psychiatry 1996;57:67-71.
71. Koran LM, Saxena S. Issues and strategies in treating refractory obsessive-compulsive disorder. CNS Spectrums 2000;5(6 Suppl 4):24-31.
72. Marazziti D, Dell'Osso L, Gemignani A, Ciapparelli A, Presta S, Di Nasso E et al. Citalopram in refractory obsessive-compulsive disorder: an open study. Int Clin Psychopharmacol 2001;16:215-9.
73. Posternak MA, Zimmerman M. Switching versus augmentation: a prospective, naturalistic comparison in depressed, treatment-resistant patients. J Clin Psychiatry 2001;62:135-42.
74. Rauch SL, O'Sullivan RL, Jenike MA. Open treatment of obsessive-compulsive disorder with venlafaxine: a series of ten cases. J Clin Psychopharmacol 1996;16(1):81-3.
75. Yaryura-Tobias JA, Neziroglu FA. Venlafaxine in obsessive-compulsive disorder. Arch Gen Psychiatry 1996;53(7):653-4.
76. Albert U, Maina G, Bogetto F. Venlafaxine versus clomipramine in the treatment of obsessive-compulsive disorder: a preliminary single-blind, 12-week, controlled study. J Clin Psychiatry 2001, submitted.
77. Jenike MA, Baer L, Minichiello WE, Rauch SL, Buttolph ML. Placebo-controlled trial of fluoxetine and phenelzine for obsessive-compulsive disorder. Am J Psychiatry 1997;154(9):1261-4.
78. Vallejo J, Olivares J, Marcos T, Bulbena A, Menchon JM. Clomipramine versus phenelzine in obsessive-compulsive disorder. A controlled clinical trial. Br J Psychiatry 1992;161:665-70.
79. Hewlett WA, Vinogradov S, Agras WS. Clonazepam treatment of obsessions and compulsions. J Clin Psychiatry 1990;51(4):158-61.
80. Hewlett WA, Vinogradov S, Agras WS. Clomipramine, clonazepam and clonidine treatment of obsessive-compulsive disorder. J Clin Psychopharmacol 1992;12(6):420-30.
81. Pato MT, Pigott TA, Hill JL, Grover GN, Bernstein S, Murphy DL. Controlled comparison of buspirone and clomipramine in obsessive-compulsive disorder. Am J Psychiatry 1991;148(1):127-9.
82. Stern L, Zohar J, Cohen R, Sasson Y. Treatment of severe, drug resistant obsessive-compulsive disorder with the 5-HT1D agonist sumatriptan. Eur Neuropsychopharmacol 1998;8(4):325-8.
83. Fux M, Levine J, Aviv A, Belmaker RH. Inositol treatment of obsessive-compulsive disorder. Am J Psychiatry 1996;153(9):1219-21.